T and B Cell Responses in Autoimmune Diseases
NCT01947036 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 68
Last updated 2016-10-26
Summary
The study aims to establish whether defects in immune cell function are shared across multiple autoimmune diseases and whether those problems match to similar genes in the cells.
Conditions
- Type 1 Diabetes Mellitus
- Multiple Sclerosis
- Arthritis, Rheumatoid
- Crohn's Disease
- Psoriasis
Sponsors & Collaborators
-
Autoimmunity Centers of Excellence
collaborator OTHER -
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Chris Cotsapas, PhD · Yale University
Eligibility
- Min Age
- 8 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-01-31
- Primary Completion
- 2015-10-31
- Completion
- 2015-10-31
Countries
- United States
Study Locations
More Related Trials
-
An Observational Study of Patients With Autoimmune Disease
NCT05842824 ·Status: NOT_YET_RECRUITING
-
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
NCT02739386 ·Status: COMPLETED
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
NCT06625671 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955 ·Status: RECRUITING ·Phase: PHASE1
-
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
NCT01466725 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT06828042 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978647 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
NCT06875960 ·Status: RECRUITING ·Phase: PHASE4
-
Follow-up Study of Individuals with Autoantibodies Against Ro/SSA and La/SSB
NCT06594861 ·Status: RECRUITING
-
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
NCT06333483 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
NCT01438489 ·Status: COMPLETED ·Phase: PHASE2
-
Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
NCT03254823 ·Status: COMPLETED
-
Autologous Polyclonal Tregs for Lupus
NCT02428309 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
NCT01262365 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
NCT00657007 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
NCT05866861 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
NCT00230035 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase II Study of M2951 in SLE
NCT02975336 ·Status: TERMINATED ·Phase: PHASE2
-
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06361745 ·Status: RECRUITING ·Phase: NA
-
FolateScan in Autoimmune Disease
NCT00588393 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous Adoptive T Regulatory Cell Transfer in Autoimmune Diseases.
NCT05566977 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
NCT06429800 ·Status: WITHDRAWN ·Phase: PHASE1
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
NCT05029336 ·Status: RECRUITING ·Phase: PHASE2